01 Pharmaceutical and API Trade — India ↔ EU

India → EU (Exports)

APIs (active pharmaceutical ingredients) to EU MA holders and CMOs; generic formulations (tablets, capsules, injectables) to EU parallel importers and distributors; biosimilars to EU hospital and retail markets; CMO/CDMO services for EU innovators; ayurvedic and herbal products (THMPD registered)

EU → India (Imports)

Patented originator formulations — high-value specialty and oncology drugs; biotech raw materials and cell culture media; laboratory analytical equipment; reference standards and pharmacopoeial substances; GMP consulting and compliance services

Possibility

Is this trade structurally viable?

Yes — India is already the world's pharmacy, supplying approximately 20% of global API volumes and a significant share of EU generic medicine imports. The infrastructure (manufacturing facilities, regulatory expertise, logistics) exists. The FTA removes the final tariff barrier. EU buyers are actively seeking Indian suppliers for supply chain diversification. The commercial possibility is not in question.

Probability

Will this specific mandate close?

High for WHO-GMP and EU GMP certified manufacturers with CEP-filed APIs or EU-registered formulations. Moderate for manufacturers who are CDSCO-compliant but not yet EU GMP inspected — they need an 18–24 month qualification pathway before first EU order. Low for non-WHO-GMP manufacturers — EU buyers will not engage without minimum certification.

Plausibility

Does the commercial logic hold?

Fully coherent. Indian generic formulations are typically priced 40–60% below EU-manufactured equivalents. Even after EU duty (6.5% current) and logistics, the margin advantage is compelling. Post-FTA, the duty saving adds a further 6.5 percentage points to the competitiveness gap. The EU's Critical Medicines Act explicitly targets diversification away from single-source Chinese API dependency — Indian manufacturers are the primary beneficiary.

Niche

API Bulk Supply

Selling active pharmaceutical ingredients to EU MA holders and generics manufacturers. Requires CEP or ASMF. Telangana and Gujarat manufacturers are the primary suppliers.

Niche

CMO/CDMO Placement

Introducing EU innovators and generics companies to Indian contract manufacturers for oral solid dosage, sterile injectables, or oncology manufacturing.

Niche

Biosimilars

Facilitating EU market access for Indian biosimilar manufacturers — complex regulatory pathway (EMA biosimilar guideline) but highest value opportunity.

Niche

Ayurvedic & Herbal (THMPD)

Traditional Herbal Medicinal Product Directive registration enables Indian herbal manufacturers to sell in EU without full clinical data. Niche but growing.

Niche

Nutraceuticals

Food supplement and functional food supply — simpler compliance path than pharmaceuticals (EFSA health claims; EU food law) but lower margins.

Niche

Packaging & Excipients

Pharmaceutical-grade packaging (blisters, vials, primary packaging) and excipients supply — often overlooked but high-volume mandate opportunity.

Historical context

How this sector evolved

• ◆ India emerged as a significant EU API supplier in the 1990s as Indian pharmaceutical manufacturers invested in WHO-GMP compliance to access WHO tender markets — the EU followed as qualification standards rose.
• ◆ The 2000s saw the first wave of EU GMP inspections of Indian facilities, with Telangana (then Andhra Pradesh) and Gujarat becoming the primary certified manufacturing hubs.
• ◆ Ranbaxy, Aurobindo, Dr. Reddy's, Lupin, and Cipla were the first Indian generic companies to receive EU registrations and penetrate the EU parallel import market in the 2000s–2010s.
• ◆ The 2010s saw increased CDSCO regulatory enforcement (following WHO and USFDA inspection failures) that led to temporary EU market access challenges — strengthening the case for pre-qualification audits.
• ◆ Post-COVID (2020–2022), the EU recognised the critical dependence on Chinese-origin APIs and formally initiated supply chain diversification policy — the EU Critical Medicines Act being the legislative outcome.

Future outlook 2025–2030

Where this is heading

• ▶ India-EU FTA (targeting 2026) will eliminate the 6.5% EU duty on generic formulations on Day 1 — adding EUR 200M+ in annual competitiveness benefit at current trade volumes.
• ▶ Biosimilars will become the highest-value pharma trade flow between India and EU — Indian biosimilar manufacturers (Biocon, Dr. Reddy's, Zydus) are already EU-EMA approved and the market is growing at 22% CAGR.
• ▶ The EU Critical Medicines Act (CMA) will create formal EU procurement preferences for non-Chinese-origin APIs in essential medicines categories — Indian manufacturers are primary beneficiaries.
• ▶ Revised Schedule M (Indian GMP 2023) will accelerate the alignment of Indian manufacturing standards with EU GMP — reducing the gap that EU inspectors have historically flagged.
• ▶ AI-enabled drug discovery partnerships between Indian CDMOs and EU biotech startups will emerge as a new mandate category — blending IT and pharma verticals.

India ↔ EU FTA impact

High impact

The India-EU FTA is a transformational event for this sector. Day 1 zero duty on generics and most APIs will accelerate the shift of EU generics procurement towards Indian manufacturers. Combined with the post-COVID-19 supply chain diversification drive and the EU's Critical Medicines Act (reducing dependence on Chinese-origin APIs), the FTA creates a compounding commercial opportunity for CDSCO/EU GMP-certified Indian manufacturers.